Industry-suitable Technologies to Protect Pharma Products against Counterfeiting

These new measures, which improve the protection of public health, will be adopted by member states on January 2, 2013. As a result, implementing labelling, tracking and tracing systems for products will likely result in additional costs to the pharmaceutical industry. Fred Jordan, CEO of AlpVision, sheds light on several cost-effective product authentication processes and features, which can be easily deployed and implemented within manufacturing plants and laboratories worldwide.

Read more

Drug Delivery: Thin Dissolving Films Begin to Come of Age

Thin Dissolving Films have been in use for industrial applications for over 25 years. The first real public awareness of edible thin films was the high-profile launch of Listerine Breath Fresheners, which spawned many copycat products. Consumers decided these were imitation rather than innovation, and growth of this new technology stalled. Chris Hatton, Business Development Director at BioFilm Ltd, explains how, with the success of Suboxone Film, a unique thin film application of a controlled drug ensuring increased patient compliance; TDF technology is once again being taken seriously for pharmaceutical and consumer healthcare products.

Read more

Supply Chain Management. It’s More than Just Freight

Effective supply chain management requires more than the ability to transport freight from A to B. It starts with procurement and involves packing, insurance, customs regulations and controlling a range of risks along the way. Lucy Jenner, Marketing Manager at Charles Kendall explains why involvement in major government programmes or niche commercial contracts makes effective management of supply chains by air, sea, rail or road vital to controlling costs and maximising profit in any business.

Read more

Applying Multi-Parameter Optimisation in Drug Discovery: Explore Broadly but Focus Quickly on High Quality Compounds

Finding a successful drug is a delicate balancing act. It is necessary to simultaneously optimise many, often conflicting, requirements to identify a compound that will ultimately become a safe and efficacious drug. Methods for guiding this process, commonly referred to as multi-parameter optimisation (MPO) have been developed. Matthew Segall, Director and Ceo at Optibrium explores how these can be applied in practice to improve productivity and efficiency in drug discovery.

Read more

Early PK-PD Modelling Significantly Facilitates Identification of the Best Drug Candidates

Pharmacokinetics and pharmacodynamics are disciplines that can straddle discovery and development when considered in their complex physiologic relationship to one another using a
sophisticated PK/PD model. Richard Slauter, Senior Director of Drug Metabolism/Pharmacokinetics and Senior Principal Study Director at MPI Research, describes how traditionally pharmacokinetics is placed in the preclinical discovery phase, because it is a series of studies that helps to narrow the number of molecules being evaluated for a particular therapeutic approach.

Read more